These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36709183)

  • 1. [Hematologic responses to avatrombopag switch in TPO-RA refractory aplastic anemia].
    Jing LP; Fan HH; Yang WR; Li Y; Li JP; Zhang L; Li Y; Zhou K; Xiong YZ; Ye L; Peng GX; Yang Y; Zhao X; Zhang FK
    Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):921-927. PubMed ID: 36709183
    [No Abstract]   [Full Text] [Related]  

  • 2. Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag.
    Zhang T; Yu Q; Chen X; Yang H; Gong Y; Zhang Y; Liu X; Yang Z; Fang Y; Yan X; Zhou X; Shi J; He G
    Front Immunol; 2024; 15():1393829. PubMed ID: 39114665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
    McQuilten Z; Heritier S; Fox L; Fox V; Young L; Blombery P; Cunningham I; Curnow J; Higgins A; Hiwase DK; Filshie R; Firkin F; Lacaze P; Mason K; Mills AK; Pepperell D; Patil S; Stevenson W; Szer J; Waters N; Wilson K; Ting S; Wood E
    BMJ Open; 2024 Jan; 14(1):e076246. PubMed ID: 38238183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
    Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
    Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China.
    Zhang Z; Hu Q; Yang C; Chen M; Han B
    Ther Adv Hematol; 2023; 14():20406207231191310. PubMed ID: 37719987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term outcomes and safety of severe aplastic anemia treated with porcine antilymphocyte globulin plus cyclosporine, with or without thrombopoietin receptor agonists: a double-center retrospective study.
    Xu S; Xiao Y; Liang X; Lu Y; Deng M
    Expert Rev Hematol; 2024; 17(4-5):181-188. PubMed ID: 38687471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markedly High Plasma Thrombopoietin (TPO) Level is a Predictor of Poor Response to Immunosuppressive Therapy in Children With Acquired Severe Aplastic Anemia.
    Elmahdi S; Muramatsu H; Narita A; Ismael O; Hama A; Nishio N; Okuno Y; Xu Y; Wang X; Takahashi Y; Kojima S
    Pediatr Blood Cancer; 2016 Apr; 63(4):659-64. PubMed ID: 26575027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence.
    Li X; Shangguan X; Wang H; Wang Q; Zhang Y; Han B; Liu R; Zhang F; Fu R; Lin Z; Miao M; Ma X; Lei M; Wu D; Liu L
    Ann Hematol; 2024 Sep; 103(9):3483-3491. PubMed ID: 39088061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution.
    Iino M; Jinguji A; Sato T; Nakadate A
    Hematology; 2022 Dec; 27(1):360-366. PubMed ID: 35306963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study.
    Ise M; Iizuka H; Kamoda Y; Hirao M; Kida M; Usuki K
    Int J Hematol; 2020 Dec; 112(6):787-794. PubMed ID: 32876852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
    Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
    Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
    [No Abstract]   [Full Text] [Related]  

  • 13. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of efficacy of immunosuppressive therapy plus recombinant human thrombopoietin for children with severe aplastic anemia].
    Zhou K; Liu CX; Li Y; Li JP; Fan HH; Zhang L; Jing LP; Peng GX; Ye L; Li Y; Song L; Zhao X; Yang WR; Wu ZJ; Chen F; Zhang FK
    Zhonghua Er Ke Za Zhi; 2017 Jul; 55(7):523-528. PubMed ID: 28728262
    [No Abstract]   [Full Text] [Related]  

  • 15. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag in children with severe aplastic anemia.
    Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group.
    Führer M; Burdach S; Ebell W; Gadner H; Haas R; Harbott J; Janka-Schaub G; Klingebiel T; Kremens B; Niemeyer C; Rampf U; Reiter A; Ritter J; Schulz A; Walther U; Zeidler C; Bender-Götze C
    Klin Padiatr; 1998; 210(4):173-9. PubMed ID: 9743949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Porcine Anti-Lymphocyte Globulin, Cyclosporine A Plus Thrombopoietin Receptor Agonists Achieved Similar Efficacy and Survival Compared to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Aplastic Anemia.
    Zhao R; Ji D; Zhou Y; Qi L; Li F
    Int J Gen Med; 2024; 17():4025-4036. PubMed ID: 39290233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China].
    Yang WR; Han B; Chang H; Wu BY; Meng FK; Ji DX; Li YM; Zheng ZJ; Fei Y; Shen JP; Hu P; Ding XQ; Zhang P; Wang YQ; Zhang FK
    Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):890-895. PubMed ID: 33333690
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia.
    Chen HF; Xu BX; Shen HS; Li ZY; Jin LJ; Tang JQ; Wang J; Zhu JJ; Qin LM; Cui QY; Ren YY; Wu TQ
    Drug Des Devel Ther; 2014; 8():1299-305. PubMed ID: 25246771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.